Aadi initiates Phase 2 trial
investigating the combination of nab-sirolimus with letrozole
for the treatment of advanced or recurrent endometrioid-type
endometrial cancer (EEC)
LOS
ANGELES, Oct. 19, 2023 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company
focused on developing and commercializing precision therapies for
patients with mTOR pathway alterations, today announced e-poster
presentations at the International Gynecologic Cancer Society
(IGCS) 2023 Annual Global Meeting, taking place November
5-7, 2023, in Seoul, Korea.
Abstract and e-poster presentation details are below:
Title: "A phase 2, open-label, single-arm, prospective,
multi-center study of nab-sirolimus plus letrozole in advanced or
recurrent endometrioid endometrial cancer"
Session Title: e-poster
Date/Time: November 5-7, 2023
Authors: Lauren E. Dockery, MD, MS; Anna Priebe, MD; Linda
Duska, MD, MPH; Angela K.
Green, MD; Cara Mathews, MD;
Fernanda Musa, MD; David O'Malley, MD; Allison Puechl, MD; Li
Ding, MS, MA; Anita N.
Schmid, PhD; Willis H.
Navarro, MD; Brian Slomovitz,
MD; Kathleen Moore, MD
Abstract highlights:
- This is a Phase 2 open-label, multi-institutional study to
evaluate the efficacy and safety of nab-sirolimus and
letrozole in patients with advanced or recurrent endometrioid
endometrial carcinoma, exploring the potential for this combination
to produce additive anti-tumor activity in patients with
endometrioid-type endometrial carcinoma (EEC)
- Dysregulation of mTOR signaling is implicated in the pathology
of EEC, in which >80% harbor PTEN or PI3K/AKT/mTOR pathway
alterations
- Prior clinical studies with mTOR inhibitors and letrozole in
endometrial cancer patients have yielded promising results
- Alternative treatment options for advanced or recurrent
endometrioid-type endometrial carcinoma (EEC) remain necessary
despite recent pivotal data demonstrating improved outcomes with
immunotherapy plus chemotherapy
- In preclinical models, intravenous nab-sirolimus
demonstrates significantly higher tumor growth inhibition,
intra-tumoral drug accumulation, and greater mTOR target
suppression compared with oral inhibitors
An encore presentation titled, "Phase 2, Multicenter, Open-label
Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring
Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION1)"
will be displayed as an e-poster during the meeting.
More information can be found on the IGCS meeting
website.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on
precision therapies for genetically defined cancers to bring
transformational therapies to cancer patients with mTOR pathway
driver alterations. Aadi received FDA approval and has
commercialized FYARRO® for the treatment of adult
patients with locally advanced unresectable or metastatic malignant
perivascular epithelioid cell tumor (PEComa).
Aadi has also initiated PRECISION1, a Phase 2 tumor-agnostic
registration-intended trial in mTOR inhibitor-naïve malignant solid
tumors harboring TSC1 or TSC2 inactivating
alterations. More information on the Company's development pipeline
is available on the Aadi website at www.aadibio.com and
connect with us on Twitter and LinkedIn.
Contact:
Marcy
Graham
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-announces-poster-presentations-on-nab-sirolimus-at-the-international-gynecologic-cancer-society-igcs-2023-annual-global-meeting-301962513.html
SOURCE Aadi Bioscience